Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2021 ARVO Annual Meeting
Allegro Ophthalmics announced that four scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, being held virtually May 1-7, 2021.
“It’s exciting to see such a diverse set of preclinical data that explores the retinal protective, anti-inflammatory, and anti-angiogenic properties of risuteganib in in vitro and in vivo models be presented at the largest meeting of eye and vision researchers in the world,” Vicken Karageozian, MD, President and CEO of Allegro Ophthalmics, said in a company news release. “Risuteganib has been shown to protect human RPE cells against oxidative stress-associated cellular dysfunction in previous preclinical studies and restore visual function in early clinical trials. At ARVO, we look forward to presenting data from five independent labs that better explain these visual gains.”
The schedule of scientific poster presentations is as follows:
- Yang, P & Jaffe, G et al. “Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells.” Saturday, May 1, 2021 from 10:15 a.m. to 12:00 p.m. EDT
- Ochoa-de la Paz, L & Quiroz-Mercado, H et al. “Neuroprotective Effect of Risuteganib on Retinal Neurons in an Excitotoxic Injury Cell Culture Model and a Mechanical Injury Rat Model.” Wednesday, May 5, 2021 from 9:00 a.m. to 10:45 a.m. EDT
- Chwa, M & Kenney, C et al. “Cell Viability and Transcriptome Changes Associated with Hydrogen Peroxide and Risuteganib Exposure in Human Retinal Cells In Vitro.” Wednesday, May 5, 2021 from 9:00 a.m. to 10:45 a.m. EDT
- Shao, Z, Campochiaro, P & Kornfield, J et al. “Suppression of Murine Choroidal and Retinal Neovascularization by Risuteganib and the Accompanying Transcriptome Changes in the OIR Retina.” Wednesday, May 5, 2021 from 2:45 p.m. to 4:30 p.m. EDT